Screener
BioCryst Pharmaceuticals BCRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Decrease in royalty financing obligations | (26,788) | (36,921) |
| Decrease in accounts payable and accrued expenses | (55,330) | (2,135) |
| Increase in deferred revenue | 10,793 | — |
| Net cash provided by operating activities | 42,551 | 13,785 |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (612) | (322) |
| Purchases of investments | (135,635) | (78,103) |
| Sales and maturities of investments | 246,931 | 134,647 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's operating cash flow?
- BioCryst Pharmaceuticals (BCRX) reported operating cash flow of $104.34M in Q2 2026.
- How has BioCryst Pharmaceuticals's operating cash flow changed year-over-year?
- BioCryst Pharmaceuticals's operating cash flow increased by 152.6% year-over-year, from $41.3M to $104.34M.
- What is the long-term trend for BioCryst Pharmaceuticals's operating cash flow?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's operating cash flow has grown at a 34.7% compound annual growth rate (CAGR), from -$142.16M to $347.37M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about BioCryst Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude